Actively Recruiting
A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-02-17
40
Participants Needed
7
Research Sites
153 weeks
Total Duration
On this page
Sponsors
M
Memorial Sloan Kettering Cancer Center
Lead Sponsor
I
Incyte Corporation
Collaborating Sponsor
AI-Summary
What this Trial Is About
The researchers are doing this study to compare 2 different GVHD prevention (prophylaxis) approaches. The researchers will see which approach is good or more effective at preventing chronic GVHD until 1 year after allogeneic hematopoietic stem cell transplantation (allo-HCT).
CONDITIONS
Official Title
A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients 18 years or older at time of consent
- Diagnosis of hematologic malignancy in remission with less than 5% blasts and no extramedullary disease in AML or MDS
- Patients with complete remission with incomplete count recovery or minimal residual disease are allowed
- Patients with lymphoma must have complete or partial response
- Donor must be related or unrelated 7-8/8 HLA-matched or related haploidentical
- Karnofsky performance score 70% or higher
- Female participants of childbearing potential (under 50 years old) must have a negative pregnancy test
- Sexually active females of childbearing potential must agree to use two forms of contraception during the study and for 3 months after last dose
- Sexually active male participants with female partners of childbearing potential must agree to use two forms of contraception and avoid sperm donation during treatment and for 3 months after last dose
You will not qualify if you...
- Recipient of CD34+ selected or engineered stem cell graft
- Treatment with in vivo T cell depletion such as anti-thymocyte globulin
- Severely impaired kidney function with serum creatinine greater than 2 mg/dL or need for dialysis
- Use of investigational drugs within 14 days before transplant
- Uncontrolled heart conditions including hypertension, arrhythmias, heart failure, unstable angina, or recent heart attack within past 6 months
- Uncontrolled psychiatric illness
- Female who is pregnant or breastfeeding
- Known allergy or sensitivity to ruxolitinib
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey, United States, 07920
Actively Recruiting
2
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
Middletown, New Jersey, United States, 07748
Actively Recruiting
3
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey, United States, 07645
Actively Recruiting
4
Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)
Commack, New York, United States, 11725
Actively Recruiting
5
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Harrison, New York, United States, 10604
Actively Recruiting
6
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, United States, 10065
Actively Recruiting
7
Memorial Sloan Kettering Nassau (Limited Protocol Activites)
Rockville Centre, New York, United States, 11553
Actively Recruiting
Research Team
D
Doris Ponce, MD, MS
CONTACT
B
Brian Shaffer, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here